The unique potential of MRG-001 was discovered initially in promoting liver regeneration and the induction of liver allograft acceptance. MRG-001 has since been tested in various other preclinical disease models with promising results.
MedRegen LLC was founded with the aid of private investors.
The MedRegen leadership partnered with a premier CDMO and invested heavily in developing a subcutaneous formulation of MRG-001 and is working towards producing an oral formulation.
All research and development was conducted and the results were filed for patent protection leading to licensing deals with MedRegen for 5 patent families.
The US FDA approved MedRegen’s IND application for a combined phase I/II trial with MRG-001 for targeting COVID-19 patients.
